Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that the CC-1001 automated hematology analyzer, which the Company developed as Japan’s first instrument for automatically measuring the number of red and white blood cells, has been registered by Japan’s National Museum of Nature and Science (Director General: Yoshihiro Hayashi) as “Essential Historical Material for Science and Technology”, also known colloquially as “MIRAI Technology Heritage.”
Sysmex Corporation (HQ: Kobe, Japan; Chairman & CEO: Hisashi Ietsugu) announces the launch of its PS-10 sample preparation system in the North American market from August 2019. By automating complicated sample preparation work for clinical laboratories, the PS-10 results in providing workflows which are more efficient and aids in standardizing clinical flow cytometry testing. Sysmex will move product development and assessment of the clinical utility with flow cytometry as analyzers forward, aiming for a global rollout of the entire clinical flow cytometry system including the PS-10.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has obtained Japanese manufacturing and marketing approval for the OncoBEAM™1 RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene2 for colorectal cancer patients. This product is the first in vitro diagnostic reagent in Japan to be used for RAS gene mutation testing for colorectal cancer using liquid biopsy. Minimally invasive and simpler than conventional physical biopsies of tumor tissue, the new testing method provides detection results on a par with the use of tumor tissue.3 As a result, this testing method reduces the physical and mental burden on patients, expands testing opportunities, and contributes to the early-stage determination of treatment methods.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), has received the 44th Inoue Harushige Prize for its “hepatic fibrosis diagnostic technology using a new glycosylation marker,” which was developed through industry-academia collaboration. The presentation ceremony was held today, July 18, 2019, at the Industry Club of Japan.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received approval on June 1, 2019 for insurance coverage for the first time in Japan for the OncoGuide NCC Oncopanel System, a gene mutation analysis set for use in cancer gene profiling (the “System”). The Company received manufacturing and marketing approval for the System on December 25, 2018.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and Osaka University (Location: Suita, Osaka, Japan; President: Shojiro Nishio) signed a comprehensive collaboration agreement on May 24, 2019 to foster innovation in the healthcare field by leveraging Sysmex’s diagnostic technologies and the knowledge Osaka University possesses in the field of information science. This agreement, […]
Sysmex Asia Pacific Pte Ltd. (Location: Singapore, President and CEO: Frank Buescher) announces that the Company has begun providing direct sales and support in India for Hematology Business. With more than 1.3 billion people, India is the world’s second most populous nation, after China, and the country’s real GDP continues to grow significantly. In addition […]
Sysmex (Thailand) Co., Ltd has successfully passed the audit for certification to ISO 9001:2015 for sales, trading, distribution, installation and servicing of clinical diagnostic equipment and health care IT products for laboratories, hospitals and healthcare organisations. As well as the import, storage and distribution of diagnostic instrumentation reagents and consumables. ISO9001:2015 certification is an international […]
On January 31, 2019, Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) launched the OncoGuide™ NCC Oncopanel System (generic name: genetic mutation analysis set (for cancer genome profiling)), for which the Company received manufacturing and marketing approval on December 25, 2018. Accordingly, in February 2019 Sysmex’s subsidiary, RIKEN GENESIS Co., Ltd. (HQ: Shinagawa-ku, Tokyo, Japan; President & CEO: Naoto Kondo), will begin providing an assay service as a healthcare service to be assessed using the OncoGuide™ NCC Oncopanel System and next-generation sequencers.